Fertility and sterility · 2005
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Palomba Stefano, Orio Francesco, Russo Tiziana, Falbo Angela, Tolino Achille, Lombardi Gaetano, Cimini Vincenzo, Zullo Fulvio
Аннотация
OBJECTIVE: To study the cell effects of raloxifene on uterine and leiomyoma tissue in postmenopausal women.
DESIGN: Prospective, randomized, double-blind, placebo-controlled study.
SETTING: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy.
PATIENT(S): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy.
INTERVENTION(S): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group).
MAIN OUTCOME MEASURE(S): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured.
RESULT(S): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls.
CONCLUSION(S): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.
DESIGN: Prospective, randomized, double-blind, placebo-controlled study.
SETTING: Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro, Italy.
PATIENT(S): Forty postmenopausal women affected by uterine leiomyomas and selected for hysterectomy.
INTERVENTION(S): Treatment for three cycles of 28 days with raloxifene at a dose of 180 mg/day orally (raloxifene group) or placebo tablets (3 tablets/day orally) (placebo group).
MAIN OUTCOME MEASURE(S): Uterine and leiomyoma dimensions were measured in each subject at entry and before surgery. On leiomyomas and homologous myometrium the proliferating cell nuclear antigen (PCNA)-positive cells/total cells (PCNA/TC) and the Bcl-2-positive cells/Bax-positive cells (Bcl-2/Bax) ratios (%), as proliferation and apoptotic indexes, respectively, were measured.
RESULT(S): After treatment, uterine and leiomyoma sizes were significantly changed in comparison with baseline and the placebo group. PCNA/TC and Bcl-2/Bax ratios were significantly higher in leiomyomas than in homologous myometrium. A significant difference was detected in PCNA/TC between the myometrium of the raloxifene and control groups, whereas no difference was observed in the Bcl-2/Bax ratio. A significant difference in PCNA/TC and Bcl-2/Bax ratios was detected in leiomyoma tissue between the raloxifene group and controls.
CONCLUSION(S): In postmenopausal women, raloxifene administration reduces uterine leiomyomas by exerting a cell antiproliferative and proapoptotic action.